In this prospective randomized study we evaluated the effect of risedronate, an aminobisphosphonate, on bone mass and turnover in patients who had undergone allogeneic stem cell transplant (SCT) for hematological malignancies. Thirty-four patients (18 females, 16 males, age 32+/-10 years) with bone mineral density (BMD)
Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies / L., Tauchmanovà; Selleri, Carmine; M., Esposito; DI SOMMA, Carolina; F., Orio Jr; G., Bifulco; Palomba, Stefano; Lombardi, Gaetano; Rotoli, Bruno; Colao, Annamaria. - In: OSTEOPOROSIS INTERNATIONAL. - ISSN 0937-941X. - 14:12(2003), pp. 1013-1019. [10.1007/s00198-003-1520-2]
Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies
PALOMBA, STEFANO;
2003
Abstract
In this prospective randomized study we evaluated the effect of risedronate, an aminobisphosphonate, on bone mass and turnover in patients who had undergone allogeneic stem cell transplant (SCT) for hematological malignancies. Thirty-four patients (18 females, 16 males, age 32+/-10 years) with bone mineral density (BMD)| File | Dimensione | Formato | |
|---|---|---|---|
|
Tauchmanovà_Beneficial-treatment-with risedronate_2003.pdf
solo gestori archivio
Note: Epub 2003 Sep 30.
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
7.9 MB
Formato
Adobe PDF
|
7.9 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
